8th CNS Drug Delivery Summit

Memo

Uniting Global Biopharma Leaders to Advance the Next Generation of Brain Delivery Technologies Long regarded as one of the greatest barriers to successful CNS drug development, brain delivery is finally entering a new era of clinical validation. Following Denali's Avlayah becoming the first FDA-approved therapy leveraging blood-brain barrier (BBB) shuttle technology, alongside encouraging advancements from Roche's Trontinemab, the industry now has clear proof that receptor-mediated transport can unlock meaningful CNS exposure for biologics. This breakthrough is accelerating investment, partnerships, and innovation across brain shuttles, targeted vectors, oligonucleotide delivery, focused ultrasound, intrathecal systems, and next-generation CNS delivery platforms. Yet major challenges remain. Developers must still improve brain exposure, demonstrate clinical translatability, optimize biodistribution, de-risk toxicity, scale manufacturing, and establish clear advantages over conventional CNS delivery routes. As programs progress beyond transferrin receptor targeting and explore novel BBB receptors, advanced imaging technologies, humanized translational models, and innovative delivery modalities, cross-functional collaboration has become essential to translating promising technologies into approved therapies. Bringing together 100+ senior leaders spanning neuroscience, biologics, protein engineering, drug delivery, DMPK, translational sciences, platform development, chemistry, business development, and investment, the 8th CNS Drug Delivery Summit is the industry's definitive forum dedicated to overcoming the delivery challenge. Join experts from Roche, Novartis, Eli Lilly, AbbVie, Alnylam, Bristol Myers Squibb, Lundbeck, Voyager Therapeutics, Biogen, Stoke Therapeutics, UCB, Harvard, JCR Pharmaceuticals and more to explore the latest BBB shuttle readouts, emerging receptor targets beyond TfR1, biodistribution and imaging innovations, focused ultrasound technologies, gene therapy delivery advances, and the investment landscape shaping the future of CNS therapeutics. URLs:Tickets: https://go.evvnt.com/3760216-2?pid=5569Brochure: https://go.evvnt.com/3760216-3?pid=5569 Date and Time: Tuesday, 01 December 2026 at 08:00 - Thursday, 03 December 2026 at 15:05 Venue details: Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, Massachusetts, 02128, United States Category: Conferences | Health | Health and Fitness Prices:Drug Developer Pricing - 3 Day Pass (Workshop Day + Conference): USD 4397.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 3099.00,Academic Pricing - 3 Day Pass (Workshop Day + Conference): USD 3797.00,Academic Pricing - 2 Day Pass (Conference Only): USD 2699.00,Service Provider Pricing - 3 Day Pass (Workshop Day + Conference): USD 5297.00,Service Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00 Speakers: Ajay Verma, Founding Scientist, Lotus Neuroscience, Ajit D'Souza, Executive Director, Drug Delivery and Devices DDCS, Eli Lilly, Akihiro Furukawa, Global Director, Research and Technology Search and Evaluation, Daiichi Sankyo, Allan Jensen, Vice President, Biotherapeutic Discovery, Lundbeck, Andrew East, Head of IDU Device Development and Manufacturing, Biogen, Bill Jackson, Founder and Chief Executive Officer, Base Pair Biotechnologies, Christopher Kadamus, Former Executive Director of Engineering, DDCS (Delivery, Device, and Connected Solutions), Eli Lilly, Didier Lefebvre, Research Fellow, Drug Delivery Sciences, AbbVie, Hugh Nuthall, Executive Director Search and Evaluation Neuroscience, Eli Lilly, James Gorman, Principal Investigator, Brain Targeting Program, Wyss Institute, Harvard Medical School, Janelle Arrambide, Head of Device Clinical, Biogen, Kaitlyn Eddy, Principal Engineer, Delivery, Device, and Connected Solutions (DDCS), Eli Lilly, Lipa Shah, Director, Novel Delivery Technologies, Novartis, Mathias Schmidt, President and Chief Executive Officer, ArmaGen and JCR Pharmaceuticals, Mathieu Nonnenmacher, Vice President, Gene Therapy, Voyager Therapeutics, Meena, Senior Vice President, Translational DMPK and Clinical Pharmacology, Stoke Therapeutics, Miles Gerson, Partner, SV Health Investors, Muthiah (Mano) Manoharan, Senior Vice President, Innovation Chemistry and Alnylam Distinguished Scientist, Alnylam Pharmaceuticals, Olivier Kitten, Founder and Chief Executive Officer, Affilogic, Paul Shughrue, Vice President, Program Leader and Head of Research, Acumen, Peter Horanyi, Senior Principal Scientist, UCB, Sarah Lamore, Senior Director, Toxicology, Wave Life Sciences, Sonu Kumar, Principal Scientist, Bristol Myers Squibb, Sophia Shi, Principal Investigator, Rowland Institute, Harvard University, Sophie Parmentier-Batteur, Head of Neurodegeneration, Novartis, Susana Correia, Director, Neuromuscular Research, Dyne Therapeutics, 53Urs Langen, Lab Head and Research Project Leader, Roche